[59] With coexisting pathologies in neurodegenerative diseases, the question remains how to distinguish primary pathologies from secondary pathologies, and specifically in this case whether non-CTE pathologies are related to CTE p-tau pathology or whether they reflect separate processes, including those associated with RHI exposure. The gene discussed is MAPT; the disease is neurodegenerative disease.